Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting.

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Kaj Blennow, Jaka Bon, Andreja Emersic, Tormod Fladby, Fernando Gonzalez-Ortiz, Milica Gregoric Kramberger, Ron Handels, Pieter Jelle Visser, K Bjørn-Eivind Kirsebom, Per Selnes, Anders Sköldunger, Andreja Speh, Santiago Timón-Reina, Ellen Vromen, Anders Wimo, Bengt Winblad

Ngôn ngữ: eng

Ký hiệu phân loại: 344.043 *Control of disease

Thông tin xuất bản: United States : Journal of Alzheimer's disease : JAD , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 726030

Thêm vào giỏ Liên kết toàn văn

BackgroundThe introduction of anti-amyloid treatments (AAT) for Alzheimer's disease (AD) has put the cost-effectiveness into focus.ObjectiveEstimate the potential cost-effectiveness of diagnostic pathways combined with AAT for early AD.MethodsDiagnostic accuracy of blood-based (BBM) and cerebrospinal fluid (CSF) biomarkers was obtained from Norwegian memory clinics using positron emission tomography (PET) as reference standard. In a health-economic model, the cost-effectiveness of three diagnostic strategies was estimated relying either on BBM (p-tau 217), CSF (Aβ

Tạo bộ sưu tập với mã QR